These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19552590)

  • 1. Cost-effectiveness analysis of raltegravir in treatment-experienced HIV type 1-infected patients in Spain.
    Chaudhary MA; Moreno S; Kumar RN; Nocea G; Elbasha E
    AIDS Res Hum Retroviruses; 2009 Jul; 25(7):679-89. PubMed ID: 19552590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of raltegravir in antiretroviral treatment-experienced HIV-1-infected patients in Switzerland.
    Elbasha EE; Szucs T; Chaudhary MA; Kumar RN; Roediger A; Cook JR; Opravil M
    HIV Clin Trials; 2009; 10(4):233-53. PubMed ID: 19723611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of raltegravir in HIV/AIDS.
    Chaudhary MA; Elbasha EH; Kumar RN; Nathanson EC
    Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):627-39. PubMed ID: 22098278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system.
    Moreno S; González J; Lekander I; Martí B; Oyagüez I; Sánchez-de la Rosa R; Casado MA
    Clin Ther; 2010 Dec; 32(13):2232-45. PubMed ID: 21316539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals in Mexico.
    Contreras-Hernandez I; Becker D; Chancellor J; Kühne F; Mould-Quevedo J; Vega G; Marfatia S
    Value Health; 2010 Dec; 13(8):903-14. PubMed ID: 21091827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A microsimulation of the cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals.
    Kühne FC; Chancellor J; Mollon P; Myers DE; Louie M; Powderly WG
    HIV Clin Trials; 2010; 11(2):80-99. PubMed ID: 20542845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
    Tunis SL; Willis WD; Foos V
    Curr Med Res Opin; 2010 Jan; 26(1):163-75. PubMed ID: 19919377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France.
    Pialoux G; Marcelin AG; Despiégel N; Espinas C; Cawston H; Finkielsztejn L; Laurisse A; Aubin C
    PLoS One; 2015; 10(12):e0145885. PubMed ID: 26714188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1-Infected Treatment-Naive Patients in Russia.
    Tremblay G; Chounta V; Piercy J; Holbrook T; Garib SA; Bukin EK; Punekar YS
    Value Health Reg Issues; 2018 Sep; 16():74-80. PubMed ID: 30296624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South Africa.
    Schneider K; Nwizu C; Kaplan R; Anderson J; Wilson DP; Emery S; Cooper DA; Boyd MA
    PLoS One; 2013; 8(2):e54435. PubMed ID: 23457450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raltegravir.
    Croxtall JD; Lyseng-Williamson KA; Perry CM
    Drugs; 2008; 68(1):131-8. PubMed ID: 18081377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.
    Raffi F; Rachlis A; Stellbrink HJ; Hardy WD; Torti C; Orkin C; Bloch M; Podzamczer D; Pokrovsky V; Pulido F; Almond S; Margolis D; Brennan C; Min S;
    Lancet; 2013 Mar; 381(9868):735-43. PubMed ID: 23306000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection.
    Mauskopf J; Brogan AJ; Talbird SE; Martin S
    AIDS; 2012 Jan; 26(3):355-64. PubMed ID: 22089378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure.
    Sendi P; Günthard HF; Simcock M; Ledergerber B; Schüpbach J; Battegay M;
    PLoS One; 2007 Jan; 2(1):e173. PubMed ID: 17245449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
    Cooper DA; Steigbigel RT; Gatell JM; Rockstroh JK; Katlama C; Yeni P; Lazzarin A; Clotet B; Kumar PN; Eron JE; Schechter M; Markowitz M; Loutfy MR; Lennox JL; Zhao J; Chen J; Ryan DM; Rhodes RR; Killar JA; Gilde LR; Strohmaier KM; Meibohm AR; Miller MD; Hazuda DJ; Nessly ML; DiNubile MJ; Isaacs RD; Teppler H; Nguyen BY;
    N Engl J Med; 2008 Jul; 359(4):355-65. PubMed ID: 18650513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
    Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
    Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of enfuvirtide for treatment-experienced patients with HIV in Italy.
    Hornberger J; Green J; Wintfeld N; Cavassini M; Rockstroh J; Giuliani G; De Carli C; Lazzarin A
    HIV Clin Trials; 2005; 6(2):92-102. PubMed ID: 15983893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raltegravir: a review of its use in the management of HIV infection in treatment-experienced patients.
    Croxtall JD; Keam SJ
    Drugs; 2009 May; 69(8):1059-75. PubMed ID: 19496631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raltegravir: the first HIV integrase inhibitor.
    Cocohoba J; Dong BJ
    Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States.
    Hornberger J; Kilby JM; Wintfeld N; Green J
    AIDS Res Hum Retroviruses; 2006 Mar; 22(3):240-7. PubMed ID: 16545010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.